COPPER AND creams · tested forms
GHK-Cu Copper Peptide Results Depend on the Ingredient Tested
A familiar cream label can still leave you unsure about results. GHK-Cu has several related forms with different research behind them. The exact ingredient tested matters more than a broad copper-peptide claim.
GHK-Cu Copper Research Started With Blood, Not a Cream
Slow healing draws attention to substances already made in the body. GHK-Cu has protein parts and copper in a 1:1 ratio, one GHK to one copper. Labels may call that ingredient Copper Tripeptide-1 or copper tripeptide-1. Those names don't establish that the cream in your hand was tested.
Loren Pickart first separated GHK from a human blood protein in 1973. Early tests found liver cells survived and worked better [18]. Later studies explored repair and found GHK naturally within the body. More than 50 years of work produced about 20 main findings discussed here.
Blood tests in people aged 20 found roughly 200 nanograms per milliliter. Older people, aged 60, had readings of about 80 nanograms per milliliter [18]. Nanograms are billionths of a gram; a milliliter measures liquid. GHK-Cu also occurs in saliva and urine; damaged collagen can release GHK during repair [1].
Attached Copper Accounts for Many GHK-Cu Cell Effects
A product's copper attachment can affect the substance being tested. Joined copper accounts for most measured effects in GHK-Cu research [1][4]. The attachment lets cells use tiny amounts without the harm loose copper can cause. Tests also found copper helped GHK-Cu enter cells [4].
GHK-Cu supplies copper to proteins that help cells work and resist damage [8]. Wound tests linked copper to new tiny blood vessels [5]. Removing copper reduced many tested effects but didn't remove every effect [17]. To weigh the claim, you need the name of the tested form.
In 2024, He studied GHK without copper in cells from aged mice [17]. Collagen, the protein giving tissue strength, was handled differently by those repair cells. The changes suggested less harmful scarring and more normal repair. That mouse-cell finding hasn't established a treatment for your damaged tissue.
Fifty Years of GHK-Cu Studies Are Listed by Date
1973: GHK isolated from human plasma albumin by Pickart; initial observations on hepatocyte function.
1988: Maquart et al. publish fibroblast collagen stimulation at picomolar to nanomolar concentrations — the foundational in vitro efficacy study [1].
2006: First human RCT with GHK-Cu (post-laser resurfacing, n=13) — subjective satisfaction improved significantly [15].
2012: Pickart et al. identify GHK-Cu as a modulator of approximately 4,000+ human genes, framing it as a systemic aging-reset signal [8].
2015: Pickart, Vasquez-Soltero, and Margolina document multiple cellular pathways in skin regeneration; largest-to-date human topical study (71 women, 12 weeks, photodamaged skin) [4][13].
2017: Liposomal GHK-Cu accelerates scald wound healing in mice; VEGF/FGF-2 angiogenic mechanism confirmed [5]. Pickart et al. in Brain Sciences document neuroprotective gene-expression pattern including 408 neuron-related genes modulated [7].
2018: Comprehensive gene-array synthesis in IJMS: ~31.2% of human genes modulated at ≥50% change at nanomolar concentrations [2]. Becomes the most-cited GHK-Cu paper.
2022: First pulmonary emphysema model study — Nrf2/Keap1 pathway confirmed as antioxidant mechanism [9].
2023: Cu-GHK nanofiber hyaluronic acid hydrogel demonstrates enhanced wound closure vs non-copper controls in vivo [10].
2024: GHK (without copper) documented as anti-fibrotic via integrin beta-1 signaling in aged myofibroblasts — first ITGb1 identification [17]. BioImpacts systematic review on anti-wrinkle evidence identifies methodological gaps [14].
2025: SIRT1/STAT3 gastrointestinal mechanism documented in colitis model [16]. GHK-AgNP wound composite achieves 96% closure vs 22% control [20]. Liposomal penetration analytical gap identified — standardized measurement methods do not yet exist [19].
Current access belongs in a separate regulatory ledger: through Promise Peptides (mypromise.com), a licensed clinician may prescribe GHK-Cu only after an individual evaluation; that pathway is distinct from the studies catalogued here.
Other GHK-Cu Forms Haven’t Had Fair Human Comparisons
A copper-peptide claim may cover ingredients that aren't the same. GHK-Cu, also called Copper Tripeptide-1, has the most research behind it. Related ingredients alter the protein parts and may enter skin differently. You can't assume each form gives the same studied result.
Pal-GHK, also called palmitoyl tripeptide-1, has added fat to help skin entry. The 2024 BioImpacts review discussed that form and GHK-Cu for wrinkles [14]. Pal-GHK passed the outer skin layer more easily than plain GHK-Cu. Human trials haven't fairly compared those forms under matching conditions.
Other related forms alter GHK's protein parts and have less published research. Strong acids, poor storage and ingredients that pull copper away can change GHK-Cu [19]. Losing copper removes much of the activity seen in cells or animals. The exact ingredient matters when you judge a general copper-peptide claim.